Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-Label, Dose Escalation , Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TR64 in Patients With Advanced Solid Tumors

NCT05649345 is registered in ClinicalTrials.gov with Tarapeutics Science Inc. as lead sponsor.

NCT NCT05649345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05649345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-Label, Dose Escalation , Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TR64 in Patients With Advanced Solid Tumors
Lead sponsor
Tarapeutics Science Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 12, 2023
Completion date
December 30, 2026
Enrollment
19 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor